Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06570213 · ClinicalTrials.gov registry record · Early Phase 1
Evaluating The Efficacy Of Combined Cognitive Processing Therapy and Stellate Ganglion Blocks for PTSD
A Early Phase 1 study, sponsored by Rush University Medical Center.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 270
- Enrollment target
NCT06570213: Recruiting Early Phase 1 study, sponsored by Rush University Medical Center.
NCT06570213 is a Early Phase 1 study that is actively recruiting participants, run by Rush University Medical Center. The registered enrollment target is 270 participants, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (409% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06570213, a Early Phase 1 study, is actively recruiting participants, sponsored by Rush University Medical Center.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 270 participants
- Enrollment target
Study Summary
The purpose of this study is to understand if we can improve the treatment for posttraumatic stress disorder (PTSD). We are looking into whether the combination of Stellate Ganglion Block (SGB) treatment and Cognitive Processing Therapy (CPT) can reduce symptoms of PTSD. CPT is a trauma-focused talk therapy that can help identify and challenge unhelpful trauma-related beliefs about oneself, others, and the world. It is known to be a highly effective talk therapy for PTSD. SGB treatment is a procedure involving an injection of local anesthetic into a bundle of nerves located in the neck that is part of the sympathetic nervous system which controls our body's response to stressful situations and blocks pain. The proposed project will systematically test whether combining CPT with SGB produces greater PTSD symptom reductions and functional improvements in the short- and longer-term up to 6-months follow-up compared to CPT (+Placebo) or SGB (+Daily Monitoring) alone.
Primary Outcome
A clinician rated assessment of PTSD
Interventions
- BEHAVIORAL Cognitive Processing Therapy
- DRUG Stellate Ganglion Block
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 270 participants |
| Start Date | 2026-04-01 |
| Est. Completion | 2029-12-31 |
| Phase | Early Phase 1 |
What NCT06570213 shows while recruiting
NCT06570213 is an interventional study that assigns participants to a tested intervention. The registered 270 participants enrollment target is mid-sized for trials with a published cap, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (409% higher).
The record links to 0 conditions, and to 2 interventions - of which Cognitive Processing Therapy is the first listed.
NCT06570213 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06570213 about?
NCT06570213 is a clinical study titled "Evaluating The Efficacy Of Combined Cognitive Processing Therapy and Stellate Ganglion Blocks for PTSD". The purpose of this study is to understand if we can improve the treatment for posttraumatic stress disorder (PTSD). We are looking into whether the combination of Stellate Ganglion Block (SGB) treatment and Cognitive Processing Therapy (CPT) can reduce symptoms of PTSD. CPT is a trauma-focused talk...
What is the current status of trial NCT06570213?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 270 participants. The study started on 2026-04-01. Estimated completion is 2029-12-31.
What interventions are being tested in trial NCT06570213?
The interventions under investigation include: Cognitive Processing Therapy (BEHAVIORAL), Stellate Ganglion Block (DRUG).
Who is sponsoring clinical trial NCT06570213?
This trial is sponsored by Rush University Medical Center, which has 320 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06570213's enrollment target sits among peer trials
270 42nd of 2000 higher than 1,959 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00801489 · 270 participants · Phase 2
Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
- NCT04372485 · 270 participants · NA
Using Mobile Health (mHealth) to Improve STI Treatment Adherence Among Adolescents
- NCT04528446 · 270 participants
The Impact of Glomerular Disorders on Bone Quality and Strength
- NCT05215327 · 270 participants · Phase 2
High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI